Teva Pharma (TEVA) call put ratio 1.5 calls to 1 put
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- Wall St slides as oil hovers near $100 on rising Middle East tensions
- Meta stock jumps 5% premarket: Analysts bullish on new Muse AI agent
- Oil nears $100 as fresh Middle East strikes raise supply risks
- How big a risk are rates to the AI boom?
- 3 reasons why S&P 500 may drop up to 10% in the near term: RBC
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
The Oracle of Omaha Goes Value Shopping in the Value Pharmaceutical Bin with Teva (TEVA)
February 15, 2018 12:26 PM ESTWith countless missteps, U.S. generics business weakness, Copaxone generic competition, and an ongoing restructuring, Teva Pharma (NYSE: TEVA) has been labeled your classic "dog" stock for the past couple of years. That all changed yesterday when Warren Buffett's Berkshire Hathaway shocked Wall Street by disclosing in their December-quarter 13F that they had accumulated a new, nearly 19 million share position in the Isreal-based pharmaceutical company.
While it is unclear if the Oracle himself pulled the trigger on the trade, all of Berkshire's lieutenants try to stick to... More
